APPENDIX A

- 1. (twice amended) A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an <u>antigen specific</u> immune response with an immunologically effective amount of a composition comprising a [lipid or lipid] phosphotidylserine /polypeptide conjugate.
- 2. The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
- 3. The method of claim 1, wherein said cancer cell is comprised within an animal.
- 4. The method of claim 3, wherein said animal is a human.
- 5. The method of claim 1, wherein said composition further comprises a pharmaceutical excipient.
- 6. The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
- 7. (amended) The method of claim 1, wherein said immune response is elicited with [lipid] phosphotidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.
- 8. The method of claim 7, wherein said polypeptide is β_2 -glycoprotein I.
- 12. (amended) A method of generating an immune response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a [phosphatidylcholine/polypeptide or a] phosphatidylserine/polypeptide conjugate composition.
- 29. The method of claim 3, wherein said animal has cancer.
- 30. The method of claim 29, wherein said animal has a tumor.

f

- 31. The method of claim 4, wherein said human has cancer.
- 32. The method of claim 31, wherein said human has a tumor.
- 33. The method of claim 12, wherein said animal comprises a cancer cell.
- 34. The method of claim 33, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
- 35. The method of claim 12, wherein said animal has cancer.
- 36. The method of claim 12, wherein said animal has a tumor.
- 37. The method of claim 12, wherein said animal is a human.
- 38. The method of claim 37, wherein said human has cancer.
- 39. The method of claim 40, wherein said human has a tumor.
- 40. The method of claim 12, wherein said animal is a mouse.
- 41. The method of claim 12, wherein said animal is a rat, a hamster, a guinea pig or a goat.
- 42. The method of claim 12, wherein said composition is administered to said animal topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
- 43. The method of claim 12, wherein said immune response is elicited with a [lipid or lipid] phosphotidylserine/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.
- 44. The method of claim [44] $\underline{43}$, wherein said polypeptide is β 2-glycoprotein I.